Page 664 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

642 PART IV Specific Malignancies in the Small Animal Patient

215. Bradbury CA, Westropp JL, Pollard RE: Relationship between 238. Blackburn AL, Berent AC, Weisse CW, et al.: Evaluation of
prostatomegaly, prostatic mineralization, and cytologic diagnosis, outcome following urethral stent placement for the treatment
Vet Radiol Ultrasound 50:167–171, 2009. of obstructive carcinoma of the urethra in dogs: 42 cases (2004-
VetBooks.ir 216. Head LL, Francis DA: Mineralized paraprostatic cyst as a potential 239. McMillan SK, Knapp DW, Ramos-Vara JA, et al.: Outcome of
2008), J Am Vet Med Assoc 242:59–68, 2013.
contributing factor in the development of perineal hernias in a dog,
J Am Vet Med Assoc 221:533–535, 2002.
217. Zekas LJ, Forrest LJ, Swainson S, et al.: Radiographic diagnosis: urethral stent placement for management of urethral obstruction
secondary to transitional cell carcinoma in dogs: 19 cases (2007-
mineralized paraprostatic cyst in a dog, Vet Radiol Ultrasound 2010), J Am Vet Med Assoc 241:1627–1632, 2012.
45:310–311, 2004. 240. Lucroy MD, Bowles MH, Higbee RG, et al.: Photodynamic therapy
218. Ackerman N: Prostatic reflux during positive contrast retrograde for prostatic carcinoma in a dog, J Vet Intern Med 19:235–237, 2003.
urethrography in the dog, Vet Radiol 24, 1983. 241. Chevalier S, Anidjar M, Scarlata E, et al.: Preclinical study of the
219. Scher HI, Scardino PT, Zelefsky MJ: Cancer of the Prostate. In novel vascular occluding agent, WST11, for photodynamic therapy
DeVita VT, Lawrence TS, Rosenberg SA, editors: Cancer: principles of the canine prostate, J Urol 186:302–309, 2011.
& practice of oncology, ed 10, Philadelphia, 2015, Wolters Kluwer, 242. Xiao Z, Owen RJ, Liu W, et al.: Lipophilic photosensitizer admin-
pp 932–980. istration via the prostate arteries for photodynamic therapy of the
220. Epstein JI, Egevad L, Amin MB, et al.: The 2014 International canine prostate, Photodiagnosis Photodyn Ther 7:106–114, 2010.
Society of Urological Pathology (ISUP) consensus conference on 243. Du KL, Mick R, Busch TM, et al.: Preliminary results of interstitial
gleason grading of prostatic carcinoma: definition of grading pat- motexafin lutetium-mediated PDT for prostate cancer, Lasers Surg
terns and proposal for a new grading system, Am J Surg Pathol Med 38:427–434, 2006.
40:244–252, 2016. 244. Huang Z, Chen Q, Luck D, et al.: Studies of a vascular-acting pho-
221. Barsanti JA, Shotts EB, Prasse K, et al.: Evaluation of diagnos- tosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine
tic techniques for canine prostatic diseases, J Am Vet Med Assoc prostate and spontaneous canine prostate cancer, Lasers Surg Med
177:160–163, 1980. 36:390–397, 2005.
222. Barsanti JA, Finco DR: Evaluation of techniques for diag- 245. Swartling J, Hoglund OV, Hansson K, et al.: Online dosimetry for
nosis of canine prostatic diseases, J Am Vet Med Assoc 185: temoporfin-mediated interstitial photodynamic therapy using the
198–200, 1984. canine prostate as model, J Biomed Opt 21:28002, 2016.
223. Leeds EB, Leav I: Perineal punch biopsy of the canine prostate 246. Hsi RA, Kapatkin A, Strandberg J, et al.: Photodynamic therapy
gland, J Am Vet Med Assoc 154:925–934, 1969. in the canine prostate using motexafin lutetium, Clin Cancer Res
224. Nyland TG, Wallack ST, Wisner ER: Needle-tract implantation 7:651–660, 2001.
following us-guided fine-needle aspiration biopsy of transitional 247. Turrel JM: Intraoperative radiotherapy of carcinoma of the prostate
cell carcinoma of the bladder, urethra, and prostate, Vet Radiol gland in ten dogs, J Am Vet Med Assoc 190:48–52, 1987.
Ultrasound 43:50–53, 2002. 248. Nolan MW, Kogan L, Griffin LR, et al.: Intensity-modulated and
225. MacLachan NJ, Kennedy PC: Tumors of the genital systems. In image-guided radiation therapy for treatment of genitourinary car-
Meuten DJ, editor: Tumors in domestic animals, Ames, IA, 2002, cinomas in dogs, J Vet Intern Med 26:987–995, 2012.
Iowa State University Press, pp 568–570. 249. Fan TM, deLorimier LP, Charney SC, et al.: Evaluation of intrave-
226. Thrall MA, Olsen PN, Freemyer FG: Cytologic diagnosis of canine nous pamidronate administration in 33 cancer-bearing dogs with
prostatic disease, J Am An Hosp Assoc 21:95–102, 1985. primary or secondary bone involvement, J Vet Intern Med 19:74–
227. Corazza M, Guidi G, Romagnoli S, et al.: Serum total prostatic and 80, 2005.
non-prostatic acid phosphatases in healthy dogs and in dogs with 250. Lattimer Jr JC: LAC, Stapleton J, et al. Clinical and clinicopatho-
prostatic diseases, J Sm Anim Pract 35:307–310, 1994. logic response of canine bone tumor patients to treatment with
228. Hardie EM, Barsanti JA, Rawlings CA: Complications of prostatic samarium-153-EDTMP, J Nucl Med 31:1316–1325, 1990.
surgery, J Am An Hosp Assoc 20:50–56, 1984. 251. Fan TM, de Lorimier LP, Garrett LD, et al.: The bone biologic
229. Hardie EM, Stone EA, Spaulding KA, et al.: Subtotal canine pros- effects of zoledronate in healthy dogs and dogs with malignant oste-
tatectomy with the neodymium:yttrium-aluminum-garnet laser, olysis, J Vet Intern Med 22:380–387, 2008.
Vet Surg 19:348–355, 1990. 252. Fan TM, Charney SC, deLorimier LP, et al.: Double-blind pla-
230. Vlasin M, Rauser P, Fichtel T, et al.: Subtotal intracapsular pros- cebo-controlled trial of adjuvant pamidronate with palliative
tatectomy as a useful treatment for advanced-stage prostatic malig- radiotherapy and intravenous doxorubicin for canine appendicular
nancies, J Sm Anim Pract 47:512–516, 2006. osteosarcoma bone pain, J Vet Intern Med 23:152–160, 2009.
231. Basinger RR, Rawlings CA, Barsanti JA, et al.: Urodynamic altera- 253. Klausner JS, Johnston SD, Bell FW: Canine prostatic diseases.
tions associated with clinical prostatic diseases and prostate surgery In Kirk RW, editor: Current veterinary therapy XII, Philadelphia,
in 23 dogs, J Am An Hosp Assoc 25:385–392, 1989. 1995, WB Saunders, pp 1103–1108.
232. Goldsmid SE, Bellenger CR: Urinary incontinence after prostatec- 254. Hawe JS: What is your diagnosis? Prostatic adenocarcinoma in a
tomy in dogs, Vet Surg 20:253–256, 1991. cat, J Am Vet Med Assoc 182:1257–1258, 1983.
233. L’Epplattenier HF, Klem B, Teske E, et al.: Partial prostatectomy 255. Hubbard BS, Vulgamott JC, Liska WD: Prostatic adenocarcinoma
using Nd:YAG laser for management of canine prostate carcinoma, in a cat, J Am Vet Med Assoc 197:1493–1494, 1990.
Vet Surg 35:406–411, 2006. 256. Caney SM, Hold PE, Day MJ, et al.: Prostatic carcinoma in two
234. Williams JM, White RAS: Tube cystostomy in the dog and cat, cats, J Sm Anim Pract 39:140–143, 1998.
J Sm Anim Pract 32:598–602, 2007. 257. LeRoy BE, Lech ME: Prostatic carcinoma causing urethral obstruc-
235. Smith JD, Stone EA, Gilson SD: Placement of a permanent tion and obstipation in a cat, J Fel Med Surg 6:397–400, 2004.
cystostomy catheter to relieve urine outflow obstruction in 258. Tursi M, Costa T, Valenza F, et al.: Adenocarcinoma of the dis-
dogs with transitional cell carcinoma, J Am Vet Med Assoc 206: seminated prostate in a cat, J Fel Med Surg 10:600–602, 2008.
496–499, 1995. 259. Zambelli D, Cunto M, Raccagni R, et al.: Successful surgical treat-
236. Mann FA, Barrett RJ, Henderson RA: Use of a retained urethral ment of a prostatic biphasic tumour (sarcomatoid carcinoma) in a
catheter in three dogs with prosatatic neoplasia, Vet Surg 21: cat, J Fel Med Surg 12:161–165, 2010.
342–347, 1992. 260. Printz C: Evolving detection and treatment methods change
237. Radhakrishnan A: Urethral stenting for obstructive uropathy utiliz- approaches to prostate cancer: US preventive services task force
ing digital radiography for guidance: feasibility and clinical out- draft recommendations now align more closely with others, Cancer
come in 26 Dogs, J Vet Intern Med 31:427–433, 2017. 124:11–12, 2018.